AstraZeneca's High-level Results From SUPERNOVA Phase 3 Covid-19 Pre-exposure Prophylaxis Trial Showed Sipavibart (AZD3152) Reduced The Incidence Of Symptomatic Covid‐19 Vs. Control (Tixagevimab/Cilgavimab Or Placebo) In Immunocompromised Patients
AstraZeneca's High-level Results From SUPERNOVA Phase 3 Covid-19 Pre-exposure Prophylaxis Trial Showed Sipavibart (AZD3152) Reduced The Incidence Of Symptomatic Covid‐19 Vs. Control (Tixagevimab/Cilgavimab Or Placebo) In Immunocompromised Patients
阿斯利康的SUPERNOVA第三期Covid-19暴露前預防試驗的高級別結果顯示，與Sipavibart（AZD3152）相比，有症狀的Covid‐19的發生率有所降低免疫功能低下患者的對照（Tixagevimab/Cilgavimab 或安慰劑）
AstraZeneca's High-level Results From SUPERNOVA Phase 3 Covid-19 Pre-exposure Prophylaxis Trial Showed Sipavibart (AZD3152) Reduced The Incidence Of Symptomatic Covid‐19 Vs. Control (Tixagevimab/Cilgavimab Or Placebo) In Immunocompromised Patients
阿斯利康的SUPERNOVA第三期Covid-19暴露前預防試驗的高級別結果顯示，與Sipavibart（AZD3152）相比，有症狀的Covid‐19的發生率有所降低免疫功能低下患者的對照（Tixagevimab/Cilgavimab 或安慰劑）
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。